Abstract
BACKGROUND: More than two-thirds of patients diagnosed with esophageal cancer will have unresectable disease. Despite advances in diagnostic and surgical techniques and improved pre- and postoperative care, the prognosis of most patients is poor. This review will focus on the use of chemotherapy for patients with metastatic disease. METHODS: A computerized (MEDLINE) search was performed to identify papers published on this topic between 1966 and 2006. RESULTS: A total of 55 trials were subsequently identified. Two randomized trials compared palliative chemotherapy with best supportive care in 180 patients with advanced esophageal cancer. CONCLUSION: Combination chemotherapy as compared to monochemotherapy is associated with significantly higher response rates but nevertheless results in similar survival. CF (Cisplatin and 5-fluorouracil) currently represents one of the most effective regimens for metastatic esophageal cancer, while among the newer combinations, irinotecan or taxane-based regimens have also given promising results. However, confirmatory and adequately powered and designed phase III studies are urgently needed to improve patients' outcomes and for better palliation of symptoms.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
